Evidence map›Paper›PMID 34059941›Full record

ReviewApplied microbiology and biotechnology2021

L-asparaginase production review: bioprocess design and biochemical characteristics.

Daniel Castro, Ana Sofia C Marques, Mafalda R Almeida, Gabriela B de Paiva, Heitor B S Bento, Danielle B Pedrolli, Mara G Freire, Ana P M Tavares, Valéria C Santos-Ebinuma

Abstract readReview
PubMed Publisher
In one paragraph

Review in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Current pharmaceutical biotechnology · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. A Structural In Silico Analysis of the Immunogenicity of L-Asparaginase fromInternational journal of molecular sciences · 2024
    Article
  18. Enzyme Engineering Strategies for the Bioenhancement of L-Asparaginase Used as a Biopharmaceutical.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Review
  19. Review
  20. Insights into diversity and L-asparaginase activity of fungal endophytes associated with medicinal plant Grewia hirsuta.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daniel CastroCICECO-Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193, Aveiro, Portugal.ORCID https://orcid.org/0000-0003-0804-4000
Ana Sofia C MarquesCICECO-Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193, Aveiro, Portugal.ORCID https://orcid.org/0000-0001-5798-0917
Mafalda R AlmeidaCICECO-Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193, Aveiro, Portugal.ORCID https://orcid.org/0000-0003-2101-8309
Gabriela B de PaivaDepartment of Engineering Bioprocess and Biotechnology, School of Pharmaceutical Sciences, UNESP - São Paulo State University, Araraquara, Brazil.ORCID https://orcid.org/0000-0003-2084-4895
Heitor B S BentoDepartment of Engineering Bioprocess and Biotechnology, School of Pharmaceutical Sciences, UNESP - São Paulo State University, Araraquara, Brazil.ORCID https://orcid.org/0000-0002-0629-3196
Danielle B PedrolliDepartment of Engineering Bioprocess and Biotechnology, School of Pharmaceutical Sciences, UNESP - São Paulo State University, Araraquara, Brazil.ORCID https://orcid.org/0000-0002-3034-6497
Mara G FreireCICECO-Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193, Aveiro, Portugal.ORCID https://orcid.org/0000-0001-8895-0614
Ana P M TavaresCICECO-Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193, Aveiro, Portugal. aptavares@ua.pt.
Valéria C Santos-EbinumaDepartment of Engineering Bioprocess and Biotechnology, School of Pharmaceutical Sciences, UNESP - São Paulo State University, Araraquara, Brazil. valeria.ebinuma@unesp.br.ORCID https://orcid.org/0000-0002-6666-6695

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the past decades, the production of biopharmaceuticals has gained high interest due to its great sensitivity, specificity, and lower risk of negative effects to patients. Biopharmaceuticals are mostly therapeutic recombinant proteins produced through biotechnological processes. In this context, L-asparaginase (L-asparagine amidohydrolase, L-ASNase (E.C. 3.5.1.1)) is a therapeutic enzyme that has been abundantly studied by researchers due to its antineoplastic properties. As a biopharmaceutical, L-ASNase has been used in the treatment of acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia (AML), and other lymphoid malignancies, in combination with other drugs. Besides its application as a biopharmaceutical, this enzyme is widely used in food processing industries as an acrylamide mitigation agent and as a biosensor for the detection of L-asparagine in physiological fluids at nano-levels. The great demand for L-ASNase is supplied by recombinant enzymes from Escherichia coli and Erwinia chrysanthemi. However, production processes are associated to low yields and proteins associated to immunogenicity problems, which leads to the search for a better enzyme source. Considering the L-ASNase pharmacological and food importance, this review provides an overview of the current biotechnological developments in L-ASNase production and biochemical characterization aiming to improve the knowledge about its production. KEY POINTS: • Microbial enzyme applications as biopharmaceutical and in food industry • Biosynthesis process: from the microorganism to bioreactor technology • Enzyme activity and kinetic properties: crucial for the final application.

Indexed as

Antineoplastic AgentsAsparaginaseAsparagineBiotechnologyDickeya chrysanthemiEscherichia coliHumansPrecursor Cell Lymphoblastic Leukemia-LymphomaRecombinant ProteinsAntineoplastic AgentsAsparaginaseAsparagineRecombinant ProteinsBiopharmaceuticalBioprocessFood industryL-asparaginase

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.